Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
Maurizio MartelliLuca CerianiGiovannino CicconeUmberto RicardiIryna KriachokBarbara BottoMonica BalzarottiAlessandra TucciSara Veronica UsaiVittorio Ruggero ZilioliElsa PenneseLuca ArcainiAnna Dabrowska-IwanickaAndrés José Maria FerreriFrancesco MerliWei Li ZhaoLuigi RigacciClaudia CelliniDavid C HodgsonCodruta IonescuCarla MinoiaElisa LucchiniMichele SpinaAlexander FossåAndrea JanikovaKate CwynarskiN George MikhaeelMats JerkemanAlice Di RoccoYana StepanishynaUmberto VitoloArmando SantoroAlessandro ReBenedetta PucciniJacopo OlivieriLuigi PetrucciSally F BarringtonBogdan MalkowskiUr MetserAnnibale VersariStephane ChauvieJan WalewskiMarek TrněnýFranco CavalliMary GospodarowiczPeter W M JohnsonAndrew John DaviesEmanuele Zuccanull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
This study, the largest randomized trial of radiotherapy in PMBCL, demonstrated favorable outcomes in patients achieving CMR with no survival impairment for those omitting irradiation.
Keyphrases
- end stage renal disease
- early stage
- radiation induced
- ejection fraction
- radiation therapy
- chronic kidney disease
- newly diagnosed
- locally advanced
- lymph node
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- metabolic syndrome
- phase iii
- rectal cancer
- insulin resistance
- ultrasound guided
- open label
- free survival